NEW YORK (TheStreet) -- Shares of Nature's Sunshine Products Inc. (NATR) are up 13.4% to $17.77 after it inked a deal with Fosun Pharma in which the joint venture will distribute and market Nature's Sunshine and Synergy products in China.
As part of the agreement, Fosun Pharma will acquire a stake of approximately 15% of Nature's Sunshine outstanding common shares.
The launch of the joint venture is subject to customary conditions, including regulatory approvals by the Chinese government.
Must Read: Warren Buffett's 25 Favorite Stocks
Separately, TheStreet Ratings team rates NATURES SUNSHINE PRODS INC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:
"We rate NATURES SUNSHINE PRODS INC (NATR) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow."